Document:

Exhibit 10.1

 

SETTLEMENT AGREEMENT AND 

GENERAL RELEASE OF ALL CLAIMS

 

This Settlement Agreement
and General Release of All Claims (“Agreement”) memorializes the settlement made by and between Key Medical Technologies,
Inc. (“Key Medical”) and Khalid Mentak (“Claimant” or “Mentak”) on the one hand and Tenon Medical,
Inc. (“Tenon”) on the other hand. Key Medical, Claimant, and Tenon are collectively referred to as “the Parties”.

 

RECITALS

 

WHEREAS, the consulting
and/or employment relationship between Tenon and Claimant ended on or about June 1, 2021;

 

WHEREAS, Claimant filed
a claim for arbitration with the American Arbitration Association (“AAA”) on or about September 2, 2021, alleging breach
of contract and other claims, which was assigned AAA Case No. 01-21-0016-3950 (“the Action”);

 

WHEREAS, Tenon denied
all of Claimant’s claims against Tenon in the Action and asserted its own counter-claim against Claimant and Key Medical,
seeking declaratory relief;

 

WHEREAS, the Parties
enter into this Agreement for the purpose of fully and forever resolving and dismissing their respective claims against one another
related to the Action, as well as certain additional potential claims described in paragraph 2b, below; and

 

WHEREAS, in exchange
for the monetary payment, representations and releases contained herein, the Parties agree to release any and all disputes, claims,
complaints, grievances, charges, actions, petitions and demands any of them may have against each other related to the Action.

 

NOW, in consideration
of the recitals above and the promises contained herein, the Parties hereby agree as follows:

 

1.            Payment
by Tenon to Key Medical: Tenon shall pay Key Medical Technologies, Inc. the total gross sum of One-Million, Two-Hundred-Thousand
Dollars and No Cents ($1,200,000). The payment shall be made within three (3) business days of when the Parties execute the Agreement.
In conjunction with the aforementioned payment, the Company may issue a Form 1099 to Key Medical, as it deems appropriate. Key
Medical and Claimant acknowledge and agree that Tenon has made no representations or warranties regarding the tax consequences
of any amounts paid pursuant to this Agreement. Key Medical and Claimant agree and understand that each is responsible for payment,
if any, of local, state, and/or federal taxes on the payment and other consideration provided hereunder by Tenon and any penalties
or assessments thereon. Key Medical and Claimant agree to pay all local, federal, and/or state taxes, if any, which are required
by law to be paid by Key Medical and/or Claimant with respect to the payment herein. Claimant and Key Medical further agree to
indemnify and hold the Tenon Releasees harmless from any taxes owed by Claimant and/or Key Medical, including interest or penalties,
on account of or related in any way to the Action and/or this Agreement, as well as any claims, demands, deficiencies, penalties,
interest, assessments, executions, judgments, or recoveries by any government agency (“Liabilities”) against Tenon
for any amounts claimed due on account of Claimant’s or Key Medical’s failure to pay or delayed payment of federal
or state taxes, or damages sustained by Tenon by reason of any such claims, including attorneys’ fees and costs. However,
Key Medical and Claimant’s liability and indemnification under this Section 1, including but not limited to the Liabilities,
shall be limited to Key Medical and Claimant’s own tax liabilities and shall not extend to any of Tenon’s tax liabilities.

 

    	 	 1	 

     

    

 

2.            Mutual
Releases.

 

a.       Release
by Key Medical and Claimant. In exchange for the promises, covenants and releases by Tenon contained herein, Key Medical and
Claimant, and each of their representatives, heirs, successors and assignees hereby completely release and forever discharge Tenon
and its current and former officers, directors, employees, agents, investors, attorneys, shareholders, administrators, affiliates,
benefit plans, plan administrators, professional employer organization or co-employer, insurers, trustees, divisions, subsidiaries,
predecessor and successor corporations, and assigns (collectively, the “Tenon Releasees”) from, and agree not to sue
concerning, or in any manner to institute, prosecute, or pursue, any and all claims, rights, demands, actions, obligations, liabilities,
attorneys' fees, claims and causes of action of any and every kind, nature and character whatsoever, which Key Medical or Claimant
may now have or has ever had against the Tenon Releasees as follows: (1) through and including June 1, 2021— from all known
and unknown claims, including damages that are unknown or unanticipated, as a full waiver of Section 1542; and (2) after June 1,
2021—from any known and unknown claims, including damages that are unknown or unanticipated, which are related to the Action
or in any way connected with Claimant’s or Key Medical’s consulting and/or employment relationships with Tenon.

 

b.       Release
by Tenon. In exchange for the promises, covenants and releases by Claimant contained herein, Tenon hereby completely releases
and forever discharges Key Medical and Claimant and his respective heirs, family members, executors, agents, and assigns (collectively,
the “Claimant Releasees") from, and agrees not to sue concerning, or in any manner to institute, prosecute, or pursue,
any and all claims, rights, demands, actions, obligations, liabilities, attorneys' fees, claims and causes of action of any and
every kind, nature and character whatsoever, , which Tenon may now have or has ever had against the Claimant Releasees, as follows:
(1) through and including June 1, 2021— from all known and unknown claims, including damages that are unknown or unanticipated,
as a full waiver of Section 1542; and (2) after June 1, 2021—from any known and unknown claims, including damages that are
unknown or unanticipated, which are related to the Action or in any way connected with Claimant’s or Key Medical’s
consulting and/or employment relationships with Tenon.

 

c.       Mutual
Release of Claims with AAA. Within five (5) business days of payment being made in accordance with Paragraph 1, above, counsel
for Claimant and Tenon shall coordinate to jointly inform AAA that all conditions of settlement have been met and jointly seek
a dismissal with prejudice of all claims and counterclaims.

 

d.       Mutual
Release of Unknown or Unsuspected Claims. It is understood and agreed that this is a full and final release covering all known,
unknown, anticipated and unanticipated injuries, debts, claims or damages of the Parties which may have arisen or may be connected
to the Action or any other act or omission related to Claimant’s consulting and/or employment relationship with Tenon through
the execution date of this Agreement. The Parties hereby waive any and all rights or benefits which they may now have, or in the
future may have, under the terms of Section 1542 of the California Civil Code, which provides as follows:

 

A general release does not extend
to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the
release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

 

    	 	 2	 

     

    

 

In that regard, the Parties realize and
acknowledge that they may have sustained losses which are presently unknown or unsuspected, that such damages and other losses
if sustained may give rise to additional complaints, actions, causes of action, claims, demands and debts in the future. Nevertheless,
the Parties acknowledge that this Agreement has been agreed upon in light of this realization, that they have had the opportunity
to consult legal counsel and that, being fully aware of this situation, each intends to hereby to release and forever discharge
the Tenon Releasees and the Claimant Releasees as follows: (1) through and including June 1, 2021—from all known and unknown
claims, including damages that are unknown or unanticipated, as a full waiver of Section 1542; and (2) after June 1, 2021—from
any known and unknown claims, including damages that are unknown or unanticipated, which are related to the Action or in any way
connected with Claimant’s or Key Medical’s consulting and/or employment relationships with Tenon.

 

3.            No
Admissions of Wrongdoing or Liability. The Parties agree that the execution of this Agreement and/or the payment of money or
benefits required by this Agreement shall not be construed as an admission of wrongdoing or liability by the Parties

 

4.            Attorneys’
Fees. In the event either party seeks to enforce the provisions of this Agreement, the prevailing party shall be entitled to
recover its costs and expenses, including reasonable attorneys’ fees.

 

5.            Knowing
and Voluntary Agreement. The Parties agree that each has had an adequate opportunity to consult legal counsel regarding this
Agreement, that each has read this Agreement and fully understands its terms and legal effect and that each is entering into this
Agreement knowingly, voluntarily, freely and without coercion.

 

6.            Binding
Effect. This Agreement shall be binding upon the Parties and their respective heirs, administrators, representatives, executives,
successors and assigns, and shall inure to the benefit of these parties, and each of them.

 

7.            Choice
of Law and Severability. The terms of this Agreement shall be governed by the laws of the State of California. In the event
that any term of this Agreement shall be found to be null or void, the remaining terms shall continue to have full force and effect.

 

8.            Complete
Agreement. The Parties understand and agree that this Agreement incorporates the entire understanding among the Parties, and
recites the sole consideration for the promises exchanged herein. This Agreement expressly supersedes any and all prior written
or oral agreements, understandings, covenants or promises between the parties. In negotiating this

Agreement, the Parties have not relied
upon any representation or promise except those expressly set forth herein. No change to or modification of this Agreement shall
be valid or binding unless it is in writing and signed by all Parties.

 

9.            Counterparts
and Use of Photocopies; Electronic Signing. This Agreement may be executed by signature of each of the Parties hereto, or their
authorized representatives, on multiple copies of this Agreement, including copies transmitted by e-mail, portable document format
(PDF) or facsimile, and upon being so executed by all Parties hereto, shall be effective as if all signatures appeared on the original
of this Agreement. A signed copy of this Agreement shall have the same force and effect as an original. The Parties agree pursuant
to California Civil Code Section 1633.7, that an electronically transmitted signature by facsimile or e-mail will suffice in lieu
of original signatures and, where practicable, to use DocuSign, an electronic signature technology, to expedite the execution of
this Agreement.

 

    	 	 3	 

     

    

 

	Dated: July 21, 2022	/s/ Khalid Mentak
	 	Khalid Mentak
	 	 	 
	Dated: July 21, 2022	KEY MEDICAL TECHNOLOGIES, INC.
	 	 	 
	 	 	 
	 	By: 	/s/ Khalid Mentak
	 	 	Khalid Mentak
	 	 	President & CEO
	 	 	 
	Dated: July 21, 2022	TENON MEDICAL, INC.
	 	 	 
	 	 	 
	 	By: 	/s/ Steven Foster
	 	 	Steven Foster 
	 	 	Chief Executive Officer

 

APPROVED AS TO FORM AND CONTENT

 

	Dated: July 21, 2022	LAW OFFICE OF ANTHONY J. SPERBER
	 	 	 
	 	 	 
	 	By: 	/s/ Anthony J. Sperber
	 	 	Anthony J. Sperber
	 	 	Attorneys for Khalid Mentak & Key Medical Technologies, Inc.
	 	 	 
	Dated: July 21, 2022	WILSON SONSINI GOODRICH & ROSATI
	 	Professional Corporation
	 	 	 
	 	By: 	/s/ Dylan J. Liddiard
	 	 	Dylan J. Liddiard
	 	 	Attorneys for Tenon Medical, Inc.

 

    	 	 4EXHIBIT 10.1

 

EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT, dated as of July 25,
2022, by and between vTv Therapeutics LLC, a Delaware limited liability company (the “Company”), and Paul Sekhri (the
“Executive”), and for certain purposes specified herein, only, vTv Therapeutics Inc., a Delaware corporation (“vTv”).

WHEREAS, the Company desires to employ the Executive,
and the Executive is willing to serve the Company for the period and upon such other terms and conditions of this Agreement.

NOW, THEREFORE, the Company and the Executive
hereby agree as follows:

1.     
Employment, Duties and Acceptance.

1.1     
Employment, Duties. The Company hereby employs the Executive for the Term (as defined in Section 2.1), to render exclusive
and full-time services to the Company as President and Chief Executive Officer of the Company, and to perform such other duties consistent
with such position as may be assigned to the Executive by the Board of Directors of the Company (the “Board”). During
the Term, the Executive shall report solely to the Board and shall be nominated to serve as a member of the Board.

1.2     
Acceptance. The Executive hereby accepts such employment and agrees to render the services described above. During the Term,
the Executive agrees to serve the Company faithfully and to the best of the Executive’s ability, to devote the Executive’s
entire business time, energy and skill to such employment, and to use the Executive’s best efforts, skill and ability to promote
the Company’s interests. The Executive further agrees to accept election, and to serve during all or any part of the Term, as an
officer or director of vTv and any Subsidiary of the Company, without any compensation therefor other than that specified in this Agreement,
if elected to any such position by the shareholders or by the Board of any Subsidiary or vTv, as the case may be. The Executive shall
not engage in any other business activity or serve in any industry, trade, professional, governmental or academic position during the
Term. Notwithstanding anything herein to the contrary, the Executive shall be permitted to serve on the board of, or as an advisor to,
an entity that does not compete with the Company, subject to providing advance written notice to the chairperson of the Board and the
Executive shall also be permitted to engage in charitable, community or personal investment activities; provided, that, such activities
and investments do not conflict with or interfere with the Executive’s obligations under this Agreement and that such investments
are in compliance with the Company’s policies and procedures.

1.3     
Location. It is anticipated that the Executive shall permitted work in New York City, subject to reasonable travel requirements
on behalf of the Company in order to fulfill Executive’s responsibilities under this Agreement (including but not limited to the
Company’s headquarters).

    	 	 	 

     

    

2.     
Term of Employment. This Agreement and the term of the Executive’s employment under this Agreement (the “Term”)
shall become effective as of August 1, 2022 (the “Effective Date”) and will continue until terminated in accordance
with Section 4.

3.     
Compensation; Benefits; Equity.

3.1     
Salary. As compensation for all services to be rendered pursuant to this Agreement during the Term, the Company agrees to
pay the Executive a base salary, payable in accordance with the Company’s normal payroll practices, at the annual rate of not less
than $480,000 less such deductions or amounts to be withheld as required by applicable law and regulations (the “Base Salary”).
In the event that the Board, from time to time, increases the Base Salary, such increased amount shall, from and after the effective date
of the increase, constitute “Base Salary” for purposes of this Agreement.

3.2     
Incentive Compensation.

3.2.1     
Annual Cash Bonus. Commencing with the 2022 fiscal year, the Executive shall be eligible to receive, to the extent earned
based on individual and corporate performance as determined by the compensation committee of vTv (the “Compensation Committee”),
an annual cash performance bonus (a “Cash Bonus”) in respect of each fiscal year that ends during the Term. Executive’s
Cash Bonus for each such fiscal year shall be targeted at least at 75% of his Base Salary in effect at the time such performance is evaluated
(the “Target Cash Bonus”), with greater or lesser amounts (including zero) paid based upon individual and corporate
performance as determined by the Compensation Committee. Subject to the Executive’s continued employment at the end of each applicable
fiscal year, the amount earned in respect of any Target Cash Bonus shall be determined by the Compensation Committee after the end of
the fiscal year for which such Target Cash Bonus is granted and shall be paid to the Executive on or prior to March 15th
of the following calendar year. For the 2022 calendar year, the Executive’s Cash Bonus, shall be prorated based on the number of
days the Executive was employed during the year by the Company divided by 365 and subjected to Executive’s employment though December
31, 2022 such pro rata amount shall be guaranteed.

3.2.2     
Equity Award. On the Effective Date, the Executive shall be granted a one-time equity award as set forth on Exhibit A. Commencing
with calendar year 2024, the Compensation Committee, in its sole discretion, may grant the Executive additional equity or equity based
awards.

3.3     
Business Expenses. The Company shall pay or reimburse the Executive for all reasonable expenses actually incurred or paid
by the Executive during the Term in the performance of the Executive’s services under this Agreement, upon presentation of expense
statements or vouchers or such other supporting information as the Company customarily may require of its officers; provided, however,

    	 	2	 

     

    

that the maximum amount available for such expenses during any period may be fixed in advance by the Board.

3.4     
Vacation. During the Term, the Executive shall be entitled to a vacation period or periods of four (4) weeks during any
calendar year taken in accordance with the vacation policy of the Company during each year of the Term.

3.5     
Fringe Benefits. During the Term, the Executive shall be entitled to all benefits for which the Executive shall be eligible
under any qualified pension plan, 401(k) plan, group insurance or other so-called “fringe” benefit plan which the Company
provides to its executive employees generally, which benefits may be amended, modified or terminated in the Company’s sole discretion.

3.6     
Administrative Support; Additional Personnel. During the Term, the Company shall hire an administrative assistant for the
Executive. During the one (1) year period following the Effective Date, the Executive shall reimburse the Company for 50% of such individual’s
base salary and bonus payments. The Company will consider hiring additional personnel to the extent reasonably required or advisable,
in each case subject to the approval by the Board and or nominating and corporate governance committee.

4.     
Termination.

4.1     
Death. If the Executive dies during the Term, the Term shall terminate forthwith upon the Executive’s death. The Company
shall pay to the Executive’s estate: (i) any Base Salary earned but not paid; (ii) a Pro Rata Cash Bonus (defined below), payable
at the time and in the manner that Cash Bonuses are paid to other executives receiving such bonus payment; and (iii) Cash Bonus for the
year prior to the year in which the Executive dies if at the time of death the Executive has earned a Cash Bonus payment for such prior
year and has not yet been paid such Cash Bonus, which prior year Cash Bonus will be paid at the time and in the manner such prior year
Cash Bonus is paid to other executives receiving such prior year Cash Bonus. The Executive shall have no further rights to any compensation
or any other benefits under this Agreement, except to the extent already earned and vested as of the day immediately prior to his death,
or as is earned, vested, or accrued by virtue of his death. “Pro Rata Cash Bonus” shall mean a pro-rata portion of
the Cash Bonus granted to the Executive for the year in which the date of termination occurs equal to a fraction, the numerator of which
is the number of calendar days during such year through (and including) the date of termination and the denominator of which is 365, with
such pro-rata portion earned in an amount based on the degree to which the applicable performance goals are achieved for the entire year
in which the date of termination occurs.

4.2     
Disability. If, during the Term the Executive is unable to perform his duties hereunder due to a physical or mental incapacity
for a period of 6 months within any 12 month period (hereinafter a “Disability”), the Company shall have the right
at any time thereafter to terminate the Term upon sending written notice of termination to the Executive. If the Company elects to terminate
the Term by reason of 

    	 	3	 

     

    

Disability, the Company shall pay to the Executive promptly after the notice of termination: (i) any Base Salary
earned but not paid, (ii) a Pro Rata Cash Bonus paid at the time and in the manner such Cash Bonus is paid to other executives receiving
such bonus payment; and (iii) a Cash Bonus for the year prior to the year in which the Executive is terminated if at the time of termination
the Executive has earned a Cash Bonus payment for such prior year and has not yet been paid such Cash Bonus, which prior year Cash Bonus
will be paid at the time and in the manner such prior year Cash Bonus is paid to other executives receiving such prior year Annual Cash
Bonus, in each case less any other benefits payable to the Executive under any disability plan provided for hereunder or otherwise furnished
to the Executive by the Company. The Executive shall have no further rights to any compensation or any other benefits under this Agreement
except to the extent already earned and vested as of the day immediately prior to his termination by reason of Disability, or as earned,
vested, or accrued by virtue of his Disability.

4.3     
Cause. The Company may at any time by written notice to the Executive terminate the Term for “Cause” (as defined
below) and, upon such termination, this Agreement shall terminate and the Executive shall be entitled to receive no further amounts or
benefits hereunder, except for any Base Salary earned but not paid prior to such termination. For the purposes of this Agreement, “Cause”
means: (i) continued willful failure by the Executive of the Executive’s material duties hereunder, (ii) conviction of any felony,
(iii) willful violation of material rules, regulations, procedures or instructions relating to the conduct of directors, employees, officers
and/or consultants of the Company that are applicable to the Executive, (iv) willful misconduct by the Executive in connection with the
performance of any material portion of the Executive’s duties hereunder, (v) breach of fiduciary obligation owed to the Company
or commission of an act of fraud or embezzlement, (vi) material breach of any provision of this Agreement, including any non-competition,
non-solicitation and/or confidentiality provisions hereof, (vii) any willful act that has a material adverse effect upon the reputation
of and/or the public confidence in the Company, or (viii) engaging in any discriminatory or sexually harassing behavior. A termination
for Cause by the Company of any of the events described in clauses (i), (iii), (vi) or (vii) shall only be effective on 15 days advance
written notification, providing the Executive the opportunity to cure, if reasonably capable of cure within said 15-day period; provided,
however, that no such notification is required if the Cause event is not reasonably capable of cure or the Board determines that
its fiduciary obligation requires it to effect a termination of the Executive for Cause immediately.

4.4     
Termination by Company without Cause or by the Executive for Good Reason. If the Executive’s employment is terminated
by the Company without Cause (other than by reason of death or Disability) or by the Executive for Good Reason (as defined below), the
Term shall terminate and the Executive shall receive: (i) as severance pay, an amount equal to one times the Base Salary payable in installments
in accordance with the Company’s normal payroll practices over such 12-month period (the “Severance Period”),
(ii) continuation of group health plan benefits to the extent authorized by and consistent with 29 U.S.C. § 1161 et seq. (commonly
known as “COBRA”) during the Severance Period, with the cost of the regular premium for such

    	 	4	 

     

    

 benefits shared in the
same relative proportion by the Company and the Executive as in effect on the date of termination (provided that the Company shall not
be required to pay any portion of the premium if such payment would result in penalty taxes imposed on the Company), and (iii) 100% of
the Target Cash Bonus for the fiscal year in which the Executive is so terminated, which Target Cash Bonus will be paid in full as part
of the Company’s next normal payroll after the Release Condition is satisfied. The Executive shall have no further rights to any
compensation or any other benefits under this Agreement. If during the Term, the Executive’s employment is terminated by the Company
without Cause or by the Executive for Good Reason, in each case within 12 months following a Change in Control (as defined in the vTv
2015 Omnibus Equity Incentive Plan as amended from time to time), then the severance pay in clause (i) of this Section 4.4 shall be increased
from “one times Base Salary to “one and a half (1.5) times Base Salary”. For purposes of this Agreement, "Good
Reason" means, without the advance written consent of the Executive: (i) a reduction in Base Salary, (ii) a material and continuing
reduction in the Executive’s responsibilities (which shall per se include the appointment of an executive chairperson of the Board
after the date hereof); (iii) the Company’s material breach of this Agreement or any agreement controlling incentive equity
awards issued by the Company to the Executive or (iv) if the Executive is required to relocate to a principal place of employment which
increases his one way commute by more than 50 miles (provided that it shall not constitute Good Reason under this clause (iv) if the Executive
is permitted to work remotely); provided, that, a termination by the Executive for Good Reason under clauses (i), (ii), (iii) or
(iv) shall be effective only if the Executive provides the Company with written notice specifying the event which constitutes Good Reason
within thirty (30) days following the occurrence of such event or date the Executive became aware or should have become aware of such
event and the Company fails to cure the circumstances giving rise to Good Reason within 30 days after such notice.

4.5     
Termination by the Executive other than for Good Reason. The Executive is required to provide the Company with 30 days’
prior written notice of termination to the Company. Subject to Section 4.4, upon termination of employment by the Executive, the Term
shall terminate and the Executive shall receive any Base Salary earned but not paid prior to such termination and shall have no further
rights to any compensation (including any Base Salary or Cash Bonus) or any other benefits under this Agreement, except to the extent
already earned and vested as of the day immediately prior to such termination.

4.6     
Release. Notwithstanding any other provision of this Agreement to the contrary, the Executive acknowledges and agrees that
any and all payments, other than payment of any accrued and unpaid Base Salary to which the Executive is entitled under this Section 4
and expenses that are reimbursable under this Agreement, are conditioned upon and subject to the Executive’s execution of a general
waiver and release (for the avoidance of doubt, the Restrictive Covenants shall survive the termination of this Agreement), in such form
as may be prepared by the Company of all claims, except for such matters covered by provisions of this Agreement which expressly survive
the termination of this Agreement. Notwithstanding anything to the contrary, the severance payments and benefits are conditioned on the
Executive’s

    	 	5	 

     

    

 execution, delivery and nonrevocation of the general waiver and release of claims within fifty-five (55) days following
the Executive’s termination of employment (the “Release Condition”). Payments and benefits of amounts which do
not constitute nonqualified deferred compensation and are not subject to Section 409A (as defined below) shall commence five (5) days
after the Release Condition is satisfied and payments and benefits which are subject to Section 409A shall commence on the 60th day after
termination of employment (subject to further delay, if required pursuant to Section 4.7.2 below) provided that the Release Condition
is satisfied.

4.7     
Section 409A.

4.7.1     
This Agreement is intended to satisfy the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code,”
and such section, “Section 409A”) with respect to amounts, if any, subject thereto and shall be interpreted and construed
and shall be performed by the parties consistent with such intent. If either party notifies the other in writing that one or more provisions
of this Agreement contravenes any Treasury Regulations or guidance promulgated under Section 409A or causes any amounts to be subject
to interest, additional tax or penalties under Section 409A, the parties shall agree to negotiate in good faith to make amendments to
this Agreement as the parties mutually agree, reasonably and in good faith are necessary or desirable, to (i) maintain to the maximum
extent reasonably practicable the original intent of the applicable provisions without violating the provisions of Section 409A or increasing
the costs to the Company of providing the applicable benefit or payment and (ii) to the extent possible, to avoid the imposition of any
interest, additional tax or other penalties under Section 409A upon the parties.

4.7.2     
To the extent the Executive would otherwise be entitled to any payment or benefit under this Agreement, or any plan or arrangement
of the Company or its Affiliates, that constitutes a “deferral of compensation” subject to Section 409A and that, if paid
during the six (6) months beginning on the date of termination of the Executive’s employment, would be subject to the Section 409A
additional tax because the Executive is a “specified employee” (within the meaning of Section 409A and as determined by the
Company), the payment or benefit will be paid or provided to the Executive on the earlier of the first day following the six (6) month
anniversary of the Executive’s termination of employment or death.

4.7.3     
Any payment or benefit due upon a termination of the Executive’s employment that represents a “deferral of compensation”
within the meaning of Section 409A shall be paid or provided to the Executive only upon a “separation from service” as defined
in Treas. Reg. § 1.409A-1(h). Each payment made under this Agreement shall be deemed to be a separate payment for purposes of Section
409A. Amounts payable under this Agreement shall be deemed not to be a “deferral of compensation” subject to Section 409A
to the extent provided in the exceptions in Treasury Regulation §§ 1.409A-1(b)(4) (“short-term deferrals”) and (b)(9)
(“separation pay plans,” including the exception under

    	 	6	 

     

    

 subparagraph (iii)) and other applicable provisions of Treasury Regulation
§ 1.409A-1 through A-6.

4.7.4     
Notwithstanding anything to the contrary in this Agreement, any payment or benefit under this Agreement or otherwise that is exempt
from Section 409A pursuant to Treasury Regulation § 1.409A-1(b)(9)(v)(A) or (C) (relating to certain reimbursements and in-kind benefits)
shall be paid or provided to the Executive only to the extent that the expenses are not incurred, or the benefits are not provided, beyond
the last day of the second calendar year following the calendar year in which the Executive’s “separation from service”
occurs; and provided further that such expenses are reimbursed no later than the last day of the third calendar year following the calendar
year in which the Executive’s “separation from service” occurs.  To the extent any expense reimbursement or the
provision of any in-kind benefit is determined to be subject to Section 409A (and not exempt pursuant to the prior sentence or otherwise),
the amount of any such expenses eligible for reimbursement, or the provision of any in-kind benefit, in one calendar year shall not affect
provision of in-kind benefits or expenses eligible for reimbursement in any other calendar year (except for any life-time or other aggregate
limitation applicable to medical expenses), and in no event shall any expenses be reimbursed after the last day of the calendar year following
the calendar year in which the Executive incurred such expenses, and in no event shall any right to reimbursement or the provision of
any in-kind benefit be subject to liquidation or exchange for another benefit.

5.     
Section 280G of the Code.

If there is a change of ownership or effective
control or change in the ownership of a substantial portion of the assets of the Company (within the meaning of Section 280G of the Code)
(a “Change in Control”) and any payment or benefit (including payments and benefits pursuant to this Agreement) that
the Executive would receive from the Company or otherwise (“Transaction Payment”) would (i) constitute a “parachute
payment” within the meaning of Section 280G of the Code and (ii) but for this sentence, be subject to the excise tax imposed by
Section 4999 of the Code (the “Excise Tax”), then the Company shall cause to be determined, before any amounts of the
Transaction Payment are paid to the Executive, which of the following two alternative forms of payment would result in the Executive’s
receipt, on an after-tax basis, of the greater amount of the Transaction Payment notwithstanding that all or some portion of the Transaction
Payment may be subject to the Excise Tax: (A) payment in full of the entire amount of the Transaction Payment (a “Full Payment”),
or (B) payment of only a part of the Transaction Payment so that the Executive receives the largest payment possible without the imposition
of the Excise Tax (a “Reduced Payment”), and the Executive shall be entitled to payment of whichever amount shall result
in a greater after-tax amount for the Executive. For purposes of determining whether to make a Full Payment or a Reduced Payment, the
Company shall cause to be taken into account all applicable federal, state and local income and employment taxes and the Excise Tax (all
computed at the highest applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a
deduction of such state and local taxes). If a Reduced Payment is made, the reduction in payments and/or benefits shall occur in the 

    	 	7	 

     

    

following
order: (1) first, reduction of cash payments, in reverse order of scheduled payment date (or if necessary, to zero), (2) then, reduction
of non-cash and non-equity benefits provided to the Executive, on a pro rata basis (or if necessary, to zero) and (3) then, cancellation
of the acceleration of vesting of equity award compensation in the reverse order of the date of grant of the Executive’s equity
awards.

6.     
Restrictive Covenant Acknowledgments; Reasonableness.

The Executive acknowledges that (i) his employment
and job duties for the Company, including under this Agreement, have resulted and will continue to result in the Executive’s access
and exposure to, and familiarity with, Confidential Information (as such term is defined in Section 10 of this Agreement) and that the
disclosure or unauthorized use of such Confidential Information by the Executive may injure the Company’s business; (ii) the Company’s
business could suffer great competitive harm if its Confidential Information should be disclosed to its competitors or to the general
public, and the Company could also suffer great harm if the Executive were to exploit the relationships which have been established with
the Company’s customers for the benefit of a competitor; (iii) the Company is entering into this Agreement in order to prevent the
disclosure of trade secrets and other competitively sensitive information relating to the Company’s business, and in order to facilitate
and induce the disclosure of Confidential Information among employees of the Company with the assurance that such information will not
be used in unfair competition against the Company; (iv) he has had the opportunity to be represented by counsel in the negotiation and
execution of this Agreement; and (v) that the covenants set forth in Sections 7 through 13 of this Agreement are reasonable in terms of
duration, scope and area restrictions and are necessary for the protection of the legitimate business interests of the Company and its
Affiliates. If, at the time of enforcement of such covenants, a court shall hold that the duration, scope or area restrictions stated
therein are unreasonable under circumstances then existing, the Executive and the Company agree that the maximum duration, scope or area
reasonable under such circumstances shall be substituted for the stated duration, scope or area and that the court shall be allowed and
directed to revise the covenants to cover the maximum period, scope and area permitted by applicable law. For purposes of Sections 6 through
11, 13, 14 and 15 of this Agreement, the term “Company” shall include the Company and its Subsidiaries.

 7.     Covenants Relating to Ownership of Notes, Records and Documents.

All memoranda, notes, records and other documents
(and copies thereof), whether in hard copy or electronic format, made or compiled by the Executive or made available to the Executive
during his employment concerning the business of the Company, including, without limitation, all technical or scientific data, ideas,
intellectual property, records, notes, experiment books, bidding data and other technical material of the Company shall be the Company's
property; provided, that, the Executive shall be entitled to keep a copy of this Agreement and compensation and benefit plans to
which the Executive is entitled to receive benefits thereunder. All such property shall, at the Company’s expense, be delivered
to Company on the date of termination of the

    	 	8	 

     

    

 Executive’s employment or upon request at any time by the Company, regardless of whether
such property contains Confidential Information.

8.     
Non-Solicitation Covenants.

8.1     
During (i) the Executive’s employment with the Company and (ii) for a period of two (2) years following termination of the
Executive’s employment for any reason (the “NS Restricted Period”), the Executive shall not, directly or indirectly,
solicit, divert or take away (or attempt to solicit, divert or take away) the business of any client, customer or supplier of the Company
(each such party, a “Restricted Party”) to the detriment of the Company (as reasonably determined by the Company) or
encourage any Restricted Party to cease doing business with the Company or to reduce the amount of business such Restricted Party does
with the Company.

8.2     
Executive shall not, for the duration of the NS Restricted Period, directly or indirectly, solicit or encourage (or cause to be
solicited or encouraged) any person who (i) is an employee of, or consultant then under contract with, the Company or (ii) who was an
employee of, or consultant with, the Company within the six-month period preceding such solicitation, to cease employment with, or the
provision of services to, the Company.

9.     
Noncompetition Covenant.

In support of the Executive’s commitment
to maintain the confidentiality of the Company’s Confidential Information, (i) during the Executive’s employment with the
Company and (ii) for a period of two (2) years following termination of the Executive’s employment for any reason (the “NC
Restricted Period”), the Executive shall not, directly or indirectly, (a) enter the employ of, or render services to (including
as a salesperson, consultant or in strategic planning role), any “Competing Business” within the “Territory” (as
such terms are defined below), (b) engage in any Competing Business within the Territory for his own account, or (c) become interested
in a Competing Business within the Territory as a partner, greater than 2% shareholder (whether or not a controlling shareholder), director,
officer or principal. For purposes of this Agreement, “Competing Business” shall be defined as any business that engages
in clinical research to develop small molecule drug(s) to treat Type 1 diabetes or to modulate any therapeutic target that is the subject
of an ongoing or planned research, development or commercialization plan by the Company as of the last date of the Executive’s employment.
For purposes of this Agreement, “Territory” shall be defined as each and all of the geographic areas and locations
where (x) the Company carries on or transacts its business, (y) the Company sells or markets its products or services, or (z) the Company’s
customers are located.

10.     
Covenant Not to Disclose Confidential Information.

The Executive agrees that he has not and shall
not, at any time during or after the Term, use, reveal or divulge (i) any trade secrets (as defined under applicable state law), (ii)
any other confidential information, including business plans, customer

    	 	9	 

     

    

 information, formulae, financial information, pricing information,
technical scientific data, technical processes clinical or pre-clinical data, protocols, research projects, results, information technology
programs or processes, database, or other information which the Company deems to be confidential or commercially sensitive, or (iii) any
material confidential information whatsoever concerning any director, officer, employee, shareholder, partner, customer or agent of the
Company or their respective family members learned by the Executive heretofore or hereafter (clauses (i) through (iii), collectively,
“Confidential Information”).

11.     
Non-disparagement Covenant.

Executive agrees that, during the Executive’s
employment with the Company and at all times thereafter, the Executive shall not issue, circulate, publish or utter any false or disparaging
statements, remarks or rumors about the Company or the customers, employees, directors, managers, officers, products, partners, shareholders
or services of the Company; provided, that, nothing herein shall prohibit the Executive from providing truthful testimony if such
testimony is required by law. The Company will instruct its senior officers and directors not issue, circulate, publish or utter any false
or disparaging statements, remarks or rumors about the Executive.

12.     
Inventions Covenant.

12.1     
During the course of employment, the Executive agrees to promptly disclose in confidence to the Company all inventions, improvements,
designs, original works of authorship, formulae, processes, algorithms, compositions of matter, computer software programs, databases,
mask works, and trade secrets (“Inventions”) that relate to the Company’s business and that the Executive makes
or conceives or first reduces to practice or creates, either alone or jointly with others, whether or not in the course of his employment,
and whether or not such Inventions are patentable, copyrightable, or protectable as trade secrets.

12.2     
The Executive understands that, under copyright laws, any copyrightable works prepared by the Executive within the course and scope
of his employment is “works for hire.” Consequently, the Company will be considered the author and owner of such works.

12.3     
The Executive agrees that all Inventions that (a) are developed using equipment, supplies, facilities or trade secrets of
the Company, (b) result from work performed by the Executive for the Company, or (c) relate to the Company’s business, including
its current or anticipated research and development, will be the sole and exclusive property of the Company. The Executive hereby assigns
and agrees to transfer to the Company any and all intellectual property, including all intellectual property rights, registrations, trade
secrets rights as well as worldwide rights in any intellectual property or other forms of protection.

12.4     
The Executive also waives and agrees never to assert any “Moral Rights” the Executive might have in or with respect
to any Invention even after 

    	 	10	 

     

    

the Executive leaves the Company. “Moral Rights” means any right (or similar right existing under
the judicial or statutory law of any country or treaty) to claim authorship of any Invention, to object or prevent modification of any
Invention, or to withdraw from circulation or to control the publication distribution of any Invention.

12.5     
The Executive agrees to execute, acknowledge, make and deliver to Company or its attorneys, without additional compensation, but
without expense to the Executive, any and all instruments, including, without limitation, United States and foreign patent applications,
trademark and copyright applications, applications for securing, protecting or registering any property rights embraced within this Agreement,
powers of attorney, assignments, oaths or affirmations, supplemental oaths and sworn statements, and to do any and all lawful acts that,
in the judgment of the Company or its attorneys, may be necessary or desirable to vest in or secure for, or maintain for the benefit of,
the Company, adequate patent and other property rights in the United States and all foreign countries with respect to any and all such
Inventions.

12.6     
The Executive has attached hereto a list describing all inventions, original works of authorship, developments, improvements, and
trade secrets which were made by the Executive prior to employment with the Company (collectively referred to as “Prior Inventions”),
which belong to the Executive, which relate to the Company’s proposed business, products or research and development, and which
are not assigned to the Company hereunder; or, if no such list is attached, the Executive represents that there are no such Prior Inventions.
The Executive agrees that he will not incorporate, or permit to be incorporated, any Prior Invention owned by the Executive or in which
he has an interest into a Company product or process without the Company’s prior written consent. Notwithstanding the foregoing
sentence, if, in the course of the Executive’s employment, the Executive incorporates into a Company product or process a Prior
Invention owned by the Executive or in which he has an interest, the Company is hereby granted and shall have a nonexclusive, royalty-free,
irrevocable, perpetual, worldwide license to make, have made, modify, use and sell such Prior Invention as part of or in connection with
such product or process.

13.     
Property of the Company.

The Executive acknowledges that
from time to time in the course of providing services pursuant to this Agreement he shall have the opportunity to inspect and use certain
property, both tangible and intangible, of the Company, and the Executive hereby agrees that said property shall remain the exclusive
property of the Company, and the Executive shall have no right or proprietary interest in such property, whether tangible or intangible,
including, without limitation, the Company’s customer and supplier lists, contract forms, books of account, computer programs and
similar property. The Executive acknowledges and agrees that he has no expectation of privacy with respect to the Company’s telecommunications,
networking or information processing systems (including, without limitation, files, e-mail messages and voice messages) and that the Executive’s
activity and any files or messages on or using any of those systems may be monitored at any time without notice as long as such monitoring
is consistent with Company-wide policies. The Executive further agrees that any property situated on the

    	 	11	 

     

    

 Company’s premises and
owned by the Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company
personnel without notice.

 

14.     
Cooperation.

The Executive agrees that during
and after her employment with the Company, the Executive will assist the Company in the defense of any claims or potential claims that
may be made or threatened to be made against the Company in any action, suit, or proceeding, whether civil, criminal, administrative,
investigative, or otherwise (each, an “Action”), and will assist the Company in the prosecution of any claims that
may be made by the Company in any Action, to the extent that such claims may relate to the Executive’s employment or the period
of the Executive’s employment by the Company. The Company shall reimburse the Executive for the Executive’s reasonable out-of-pocket
expenses, any pay the Executive at a customary hourly rate for his time, associated with such cooperation following her termination of
employment; provided, that the Executive shall not receive any pay for the first 10 hours of cooperation.

 

15.     
Remedies.

15.1     
The Executive and the Company agree and acknowledge that any breach or threatened breach of this Agreement by the Executive would
result in continuing material and irreparable harm and injury to the Company and/or its Affiliates, and because either (i) money damages
will not provide an adequate remedy to the Company or (ii) it would be difficult or impossible to establish the full monetary value of
such damages, the Company shall be entitled to seek equitable relief (including, without limitation, specific performance, account for
profits, or injunctive relief) in the event of the Executive’s breach or threatened breach of this Agreement. Any equitable relief
is in addition to any other available remedy, including, damages.

15.2     
In addition to any other remedy which may be available (i) at law or in equity or (ii) pursuant to any other provision
of this Agreement, the continued payments by the Company of Base Salary and the regular premium for group health benefits pursuant to
Section 4.4 will cease as of the date on which such violation first occurs. In addition, if the Executive breaches any of the Restrictive
Covenants and the Company obtains injunctive relief with respect thereto (that is not later reversed or otherwise terminated or vacated
by judicial order), the period during which the Executive is required to comply with that particular covenant shall be extended by the
same period that the Executive was in breach of such covenant prior to the effective date of such injunctive relief.

15.3     
Notwithstanding anything to the contrary contained herein, nothing in this Agreement shall prohibit Executive from reporting possible
violations of federal law or regulation to or otherwise cooperating with or providing information requested by any governmental agency
or entity, including, but not limited to, the Department of Justice, the Securities and Exchange Commission, the United States Congress,
any state legislative and executive agency, and any agency Inspector General, 

    	 	12	 

     

    

or making other disclosures that are protected under the
whistleblower provisions of federal law or regulation. Executive does not need the prior authorization of the Company to make any such
reports or disclosures and Executive is not required to notify the Company that Executive has made such reports or disclosures.

16.     
Executive Representation.

16.1     
The Executive hereby represents and warrants that (i) the execution, delivery and performance of this Agreement by the Executive
does not and will not conflict with, breach, violate, or cause a default under any agreement, contract, or instrument to which the Executive
is a party or any judgment, order, or decree to which the Executive is subject and (ii) the Executive is not a party or bound by any other
employment agreement, noncompetition agreement, or confidentiality agreement with any other person or entity, other than the Company.
The Company shall have a right to provide a copy of this Agreement to any new employer of the Executive during the Term and for three
(3) years thereafter.

16.2     
Prior to execution of this Agreement, the Executive was advised by the Company of the Executive’s right to seek independent
advice from an attorney of the Executive’s own selection regarding this Agreement. The Executive acknowledges that the Executive
has entered into this Agreement knowingly and voluntarily and with full knowledge and understanding of the provisions of this Agreement
after being given the opportunity to consult with counsel and has in fact consulted with counsel. The Executive further represents that
in entering into this Agreement, the Executive is not relying on any statements or representations made by any of the Company’s
directors, officers, employees or agents which are not expressly set forth herein, and that the Executive is relying only upon the Executive’s
own judgment and any advice provided by the Executive’s attorney. The Executive acknowledge and agrees that he was represented
by counsel and expressly agrees to all the provisions in this Agreement, including, without limitation, the governing law, venue and
forum in Section 18.

17.     
Notices.

All notices, requests, consents, and other communications
required or permitted to be given hereunder shall be in writing and shall be deemed to have been duly given if delivered personally, sent
by overnight courier or mailed first class, postage prepaid, by registered or certified mail (notices mailed shall be deemed to have been
given on the date mailed), as follows (or to such other address as either party shall designate by notice in writing to the other in accordance
herewith):

If to the Company, to:

vTv Therapeutics LLC

3980 Premier Drive, Suite 310

High Point, NC 27265

Attention: Chairperson of the Board

    	 	13	 

     

    

If to vTv, to:

 

vTv Therapeutics Inc.

3980 Premier Drive, Suite 310

High Point, NC 27265

Attention: Chairperson of the Board

If to the Executive, to:

Paul Sekhri

130 West 19th Street, Apt. THE

New York, NY 10011

Such address as shall most currently appear on the records of
the Company.

18.     
Governing Law; Dispute Resolution.

18.1     
It is the intent of the parties hereto that all questions with respect to the construction of this Agreement and the rights and
liabilities of the parties hereunder shall be determined in accordance with the laws of the State of Delaware, without regard to principles
of conflicts of laws thereof that would call for the application of the substantive law of any jurisdiction other than the State of Delaware.

18.2     
Each party irrevocably agrees for the exclusive benefit of the other that any and all suits, actions or proceedings relating to
this Agreement (a “Proceeding”) shall be maintained in either the courts of the State of Delaware or the federal District
Courts sitting in Wilmington, Delaware (collectively, the “Chosen Courts”) and that the Chosen Courts shall have exclusive
jurisdiction to hear and determine or settle any such Proceeding and that any such Proceedings shall only be brought in the Chosen Courts.
Each party irrevocably waives any objection that it may have now or hereafter to the laying of the venue of any Proceedings in the Chosen
Courts and any claim that any Proceedings have been brought in an inconvenient forum and further irrevocably agrees that a judgment in
any Proceeding brought in the Chosen Courts shall be conclusive and binding upon it and may be enforced in the courts of any other jurisdiction.

18.3     
Each of the parties hereto agrees that this Agreement involves at least $100,000 and that this Agreement has been entered into
in express reliance on Section 2708 of Title 6 of the Delaware Code. Each of the parties hereto irrevocably and unconditionally agrees
that (i) to the extent such party is not otherwise subject to service of process in the State of Delaware, it will appoint (and maintain
an agreement with respect to) an agent in the State of Delaware as such party’s agent for acceptance of legal process and notify
the other parties hereto of the name and address of said agent, (ii) service of process may also be made on such party by pre-paid certified
mail with a validated proof of mailing receipt constituting evidence of valid service sent to such party at the address set forth in Section
17 of this Agreement, as such address

    	 	14	 

     

    

 may be changed from time to time pursuant hereto, and (iii) service made pursuant to clause (i)
or (ii) above shall, to the fullest extent permitted by applicable law, have the same legal force and effect as if served upon such party
personally within the State of Delaware.

19.     
General.

19.1     
JURY TRIAL WAIVER. THE PARTIES EXPRESSLY AND KNOWINGLY WAIVE ANY RIGHT TO A JURY TRIAL IN THE EVENT ANY ACTION ARISING UNDER
OR IN CONNECTION WITH THIS AGREEMENT OR THE EXECUTIVE’S EMPLOYMENT WITH THE COMPANY IS LITIGATED OR HEARD IN ANY COURT.

19.2     
Continuation of Employment. Unless the parties otherwise agree in writing, continuation of the Executive’s employment
with the Company beyond the expiration of the Term shall be deemed an employment “at will” and shall not be deemed to extend
any of the provisions of this Agreement, and the Executive’s employment may thereafter be terminated “at will” by the
Executive or the Company and the Executive will be entitled to fringe benefits which the Executive is eligible to receive for so long
as the Executive continues to be employed with the Company and the Executive shall be eligible for severance in accordance with the terms
of the Company’s severance policy then in effect. Notwithstanding the foregoing, the Executive shall be subject to the Restrictive
Covenants set forth in Sections 7 through 13 of this Agreement for the NC Restricted Period, the NS Restricted Period, or such other duration
specified in the section of this Agreement applicable to such Restrictive Covenant, as applicable.

19.3     
Headings. The section headings contained herein are for reference purposes only and shall not in any way affect the meaning
or interpretation of this Agreement.

19.4     
Entire Agreement. This Agreement sets forth the entire agreement and understanding of the parties relating to the Executive’s
employment by the Company, and supersedes all prior agreements, arrangements and understandings, written or oral, relating to the Executive’s
employment by the Company and its Affiliates including, without limitation, effective as of the Effective Date (any term sheets), and
any severance, retention, change in control or similar types of benefits. No representation, promise or inducement has been made by either
party that is not embodied in this Agreement, and neither party shall be bound by or liable for any alleged representation, promise or
inducement not so set forth.

19.5     
Assignment; Successors. This Agreement, and the Executive’s rights and obligations hereunder, may not be assigned
by the Executive. The Company may assign its rights, together with its obligations, hereunder (i) to any Affiliate or (ii) to
third parties in connection with any sale, transfer or other disposition of all or substantially all of the business or assets of the
Company; in any event the obligations of the Company hereunder shall be binding on its successors or assigns, whether by merger, consolidation
or acquisition of all or substantially all of its business

    	 	15	 

     

    

 or assets. For the avoidance of doubt, the Company may assign this Agreement
to vTv in connection with any internal reorganization.

19.6     
Waiver. This Agreement may be amended, modified, superseded, canceled, renewed or extended and the terms or covenants hereof
may be waived, only by a written instrument executed by all of the parties hereto, or in the case of a waiver, by the party waiving compliance.
The failure of either party at any time or times to require performance of any provision hereof shall in no manner affect the right at
a later time to enforce the same. No waiver by either party of the breach of any term or covenant contained in this Agreement, whether
by conduct or otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such
breach, or a waiver of the breach of any other term or covenant contained in this Agreement.

19.7     
Withholding Taxes. The Company may withhold from any amounts payable under this Agreement such federal, state, local and
other taxes as may be required to be withheld pursuant to any applicable law or regulation.

20.     
Subsidiaries and Affiliates.

20.1     
As used herein, the term “Subsidiary” shall mean any corporation or other business entity controlled directly
or indirectly by the corporation or other business entity in question, and the term “Affiliate” shall mean and include
any corporation or other business entity directly or indirectly controlling, controlled by or under common control with the corporation
or other business entity in question.

[Remainder of Page Intentionally
Left Blank]

 

 

 

 

 

 

 

 

 

 

    	 	16	 

     

    

IN WITNESS WHEREOF, the parties have executed
this Agreement as of the date first above written.

 

	PAUL SEKHRI	 
	 	 	 
	By:	/s/ Paul Sekhri	 
	Name:	Paul Sekhri	 
	 	 	 
	 	 	 
	 	 	 
	VTV THERAPEUTICS LLC
	 	 	 
	By:	/s/ Rich Nelson	 
	Name:	Rich Nelson	 
	Title:	
    Interim CEO
	 

 

 

 

 

 

 

 

 

 

 

    	 	17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]